Long-term results of intravitreal ranibizumab treatment for neovascular age-related macular degeneration in clinical practice

2013 ◽  
Vol 8 (1) ◽  
pp. 37-40
Author(s):  
Luis Arias
Keyword(s):  
Clinical Practice ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Long Term Results ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Ranibizumab Treatment

scholarly journals Long term intravitreal ranibizumab treatment for exsudative age-related macular degeneration

2013 ◽  
Vol 154 (45) ◽  
pp. 1790-1797 ◽  
Author(s):  
Regina Lukács ◽  
Miklós Resch ◽  
András Papp ◽  
Antal Szabó ◽  
Ágnes Borbándy ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Retinal Thickness ◽  
Age Related Macular Degeneration ◽  
Central Retinal Thickness ◽  
First Year ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Pro Re Nata ◽  
Ranibizumab Treatment

Introduction: The results of intravitreal ranibizumab treatment for exsudative age-related macular degeneration have been favourable until this time. Aim: To evaluate the two-year functional and anatomic results of intravitreal ranibizumab treatment. Method: 46 patients (age: 75±9.1 years) were included in a prospective single center study. Treatment regimen was the following: monthly 0.5 mg ranibizumab was administered in the first 3 months, and later as required (pro re nata). The change of best corrected visual acuity and central retinal thickness was followed. Results: The visus change at the end of the follow-up time was not statistically significant compared to baseline (p = 0.760) and the at the end of the first year (p = 0.154). Central retinal thickness decreased significantly compared to baseline (p = 0.000001), but the change was not statistically significant compared to the end of the first year (p = 0.875). Conclusions: Patients with neovascular macular degeneration treated with intravitreal ranibizumab using pro re nata regimen have stable visus for long term, and the exsudation could be reduced efficiently. Orv. Hetil., 154(45), 1790–1797.

Long-Term Results of Radiotherapy for Age-Related Macular Degeneration

2001 ◽  
pp. 103-109
Author(s):  
G.J. Bergink ◽  
C.B. Hoyng ◽  
R.W.M. van der Maazen ◽  
J.R. Vingerling ◽  
W.A.J. van Daal ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Long Term Results ◽  
Age Related

CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE

Retina ◽  
2015 ◽  
Vol 35 (9) ◽  
pp. 1743-1749 ◽  
Author(s):  
Eric H. Souied ◽  
Hassiba Oubraham ◽  
Gérard Mimoun ◽  
Salomon Y. Cohen ◽  
Stéphane Quere ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Clinical Practice ◽  
Macular Degeneration ◽  
Daily Clinical Practice ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

scholarly journals Intravitreal Ranibizumab Treatment and Treatment Regimens in Wet-Form (Neovascular) Age-Related Macular Degeneration

2017 ◽  
pp. 189-197
Keyword(s):  
Macular Degeneration ◽  
Progressive Disease ◽  
Vision Loss ◽  
Age Related Macular Degeneration ◽  
Therapeutic Tool ◽  
Intravitreal Ranibizumab ◽  
Treatment Regimens ◽  
Age Related ◽  
Ranibizumab Treatment

Age-related macular degeneration (AMD) is a chronic and progressive disease of the central retina that causes vision loss in people over 50 years of age. With an understanding of the role of VEGF in AMD, intravitreal anti-VEGF agents are used as the most important therapeutic tool in the management of AMD. In this review we try to discuss intravitreal ranibizumab treatment and treatment regimens in wet (neovascular) age-related macular degeneration.

Sign in / Sign up

Export Citation Format

Share Document